Type 2 diabetes mellitus is a long-term medical illness in which the body either becomes
resistant to insulin or fails to produce it sufficiently. Mostly, combinatorial therapy is
required to control blood glucose levels. However, combinatorial therapy has detrimental side
effects. The prevalence of the cases and subsequent increases in medical costs of the same intimidate
human health globally. While there have been a lot of studies focused on developing diabetic
regimens that work to lower blood glucose levels, their effectiveness is short-lived because of unfavorable
side effects, such as weight gain and hypoglycemia. In recent years, the PIN1 (protein
interacting with NIMA) enzyme has attracted the attention of researchers. Previous studies suggested
that PIN1 may act on the various substrates that are involved in the progression of T2DM
and also help in the management of diabetes-related disorders. Thus, the focus of the current review
is to examine the correlation between PIN1, T2DM and its related disorders and explore the
possibility of developing novel therapeutic targets through PIN1 inhibition.